>>Signaling Pathways>> PROTAC>> Ligand for Target Protein for PROTAC>>DUPA

DUPA

Catalog No.GC34563

DUPA는 글루타메이트 요소의 한 종류에 속하며, 전립선암 세포에 세포독성 약물을 선택적으로 전달하기 위해 약물 접합체의 표적 부분으로 사용됩니다.

Products are for research use only. Not for human use. We do not sell to patients.

DUPA Chemical Structure

Cas No.: 302941-52-2

Size 가격 재고 수량
5mg
US$108.00
재고 있음
10mg
US$180.00
재고 있음
50mg
US$675.00
재고 있음
100mg
US$1,080.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells[1][2].

DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer[1]. The DUPA-indenoisoquinoline conjugate exhibits an IC50 in the low nanomolar range in 22RV1 cell cultures[2].

The DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity, as determined by loss of body weight and death of treated mice[2].

[1]. Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80. [2]. Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103.

리뷰

Review for DUPA

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DUPA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.